循环肿瘤HPV16 DNA定量——HPV相关口咽癌接受根治性放化疗患者无进展生存的预后工具
本研究基于ARTSCAN III试验中p16阳性口咽癌患者,分析136例患者治疗前及治疗结束时血液ctHPV16-DNA水平,发现治疗前可检出者占108/136,治疗结束时74%清除;基线水平和AUC-ctHPV16DNA均与无进展生存和总生存相关,AUC在多变量分析中仍为独立预后因素。
要点
- 136例p16阳性口咽癌患者中,治疗前qPCR可检出ctHPV16-DNA者108例,治疗结束时74%清除。
- 基线ctHPV16-DNA水平与肿瘤负荷显著相关(R=0.39,p<0.001)。
- AUC-ctHPV16DNA在包含肿瘤体积和治疗分配的多变量分析中仍为无进展生存的显著预后标志。
核心结论
- ctHPV16-DNA是HPV相关口咽癌的独立预后因素。
研究设计与样本
- 研究队列为ARTSCAN III试验中招募的p16阳性口咽癌患者,该试验比较放疗联合顺铂与放疗联合西妥昔单抗。
- 分析136例患者治疗开始前和治疗结束时的血液样本,采用实时定量PCR(qPCR)定量ctHPV16-DNA。
- 采用Pearson回归分析评估ctHPV16-DNA水平与肿瘤负荷的相关性,采用AUC计算和单变量及多变量Cox比例风险模型评估预后价值。
主要发现
- 136例患者中108例在治疗开始前可检出ctHPV16-DNA,其中74%在治疗结束时清除。
- 疾病负荷与基线ctHPV16-DNA水平显著相关(R=0.39,p<0.001)。
- 较低基线水平和AUC-ctHPV16DNA均与改善的无进展生存相关(p=0.01和p<0.001),也与改善的总生存相关(p=0.013和p=0.002),但与局部肿瘤控制无关(p=0.12和p=0.2)。
- AUC-ctHPV16DNA与无进展生存的关联更强(Cox回归分析中似然比检验10.5 vs 6.5)。
- 在包含肿瘤体积(GTV-T)和治疗分配(顺铂 vs 西妥昔单抗)的多变量分析中,AUC-ctHPV16DNA仍为无进展生存的显著预后标志。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Circulating tumour (ct) human papillomavirus (HPV) DNA is detectable in HPV-related oropharyngeal carcinoma (OPSCC) patients and has the potential to become an important clinical tool. This study aimed to evaluate the prognostic significance of ctHPV16-DNA kinetics during treatment with chemoradiotherapy in HPV-related OPSCC. Patients with p16-positive OPSCC recruited to the ARTSCAN III trial, comparing radiotherapy plus cisplatin with radiotherapy plus cetuximab, constituted the study cohort. MATERIALS AND METHODS: Blood samples before start and at the end of treatment of 136 patients were analysed. ctHPV16-DNA was quantified by real-time (q)PCR. The correlation between ctHPV16-DNA levels and tumour burden was investigated with Pearson regression analysis. The prognostic value of ctHPV16-DNA levels at baseline and decline during treatment was evaluated by area-under-the-curve (AUC) calculations and analysed with univariable and multivariable Cox proportional hazards models. RESULTS: ctHPV16-DNA was detectable with qPCR in 108/136 patients before start of treatment and cleared in 74% of these patients at the end of treatment. Disease burden was significantly correlated with baseline ctHPV16-DNA levels (R = 0.39, p=<0.001). Both lower baseline levels and AUC-ctHPV16DNA were associated with improved progression-free survival (p = 0.01 and p < 0.001), overall survival (p = 0.013 and p = 0.002), but not local tumour control (p = 0.12 and p = 0.2, respectively), with a stronger association for AUC-ctHPV16DNA (likelihood ratio test 10.5 vs 6.5 in Cox regression analyses of progression-free survival). In multivariable analysis including tumour volume (GTV-T) and treatment allocation (cisplatin vs cetuximab), AUC-ctHPV16DNA remained a significant prognostic marker of progression-free survival. CONCLUSION: ctHPV16-DNA is an independent prognostic factor in HPV-related OPSCC.
引用
- Adrian G, Forslund O, Pedersen L, et al. Circulating tumour HPV16 DNA quantification - A prognostic tool for progression-free survival in patients with HPV-related oropharyngeal carcinoma receiving curative chemoradiotherapy. Radiother Oncol. 2023. PMID: 37385383. doi:10.1016/j.radonc.2023.109773
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。